Latest Breaking News On - ஸ்தாபனம் ஆய்வகங்கள் ஹோல்டிங்ஸ் - Page 1 : comparemela.com
Establishment Labs Holdings Inc : Establishment Labs to Launch Motiva Flora Tissue Expander at London Breast Meeting on September 2, 2021
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Establishment Labs : Announces Departure of CFO and Appointment of Raj Denhoy as Interim CFO
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Establishment Labs Announces Departure of CFO and Appointment of Raj Denhoy as Interim CFO
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Markets
In a report released today, Marie Thibault from BTIG reiterated a Buy rating on Accuray (ARAY – Research Report), with a price target of $9.00. The company’s shares closed last Tuesday at $5.32, close to its 52-week high of $6.02.
According to TipRanks.com, Thibault is a 5-star analyst with an average return of 74.2% and a 64.9% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Irhythm Technologies, and Edwards Lifesciences.
Accuray has an analyst consensus of Moderate Buy, with a price target consensus of $8.00.
The company has a one-year high of $6.02 and a one-year low of $1.75. Currently, Accuray has an average volume of 790.2K.
Markets
In a report released yesterday, Marie Thibault from BTIG maintained a Hold rating on Masimo (MASI – Research Report). The company’s shares closed last Monday at $242.67.
According to TipRanks.com, Thibault is a 5-star analyst with an average return of 74.1% and a 61.5% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Edwards Lifesciences, and Irhythm Technologies.
Masimo has an analyst consensus of Moderate Buy, with a price target consensus of $297.50, implying a 20.3% upside from current levels. In a report issued on April 12, Needham also assigned a Hold rating to the stock.
Based on Masimo’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $295 million and net profit of $70.67 million. In comparison, last year the company earned revenue of $248 million and had a net profit of $52.92 million.